evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

9 questions · 9 findings · 2 reviews · All outcomes

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 9 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Cyclosporin (systemic; 10 mg/kg/day for 16 weeks) vs Colchicine (systemic; 1 mg daily)

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review

Cyclosporin A in orabase (topical) vs Placebo (orabase)

Oral ulcers (number, size, healing time) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    Ergun 1997 (cyclosporin A in orabase vs placebo orabase, 24 patients; high risk of reporting bias): no data were presented; authors reported no clinical improvement in the number, size, and healing time of ulcers for…
    1 study · 24 participants
    GRADE not reported

Cyclosporin (systemic; 10 mg/kg/day for 16 weeks) vs Colchicine (systemic; 1 mg daily)

Alleviation of oral aphthous ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Cyclosporin (systemic; 10 mg/kg/day for 16 weeks) led to higher alleviation of oral aphthous ulcers compared with colchicine (systemic; 1 mg daily); GRADE not reported.

1 finding from 1 review

Topical interventions (sucralfate, interferon-alpha, cyclosporin A) vs placebo

Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
    Studies not reported
    GRADE not reported

Topical interventions (sucralfate, interferon-alpha, cyclosporin A) vs placebo

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
    Studies not reported
    GRADE not reported

Topical interventions (sucralfate, interferon-alpha, cyclosporin A) vs placebo

Pain associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
    Studies not reported
    GRADE not reported

Topical interventions (sucralfate, interferon-alpha, cyclosporin A) vs placebo

Episode duration associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
    Studies not reported
    GRADE not reported

Higher JIA disease activity/severity (e.g., high JADAS/activity scores, polyarticular RF-negative subtype, active disease, anti-TNFalpha or cyclosporine medication) vs Lower JIA disease activity / inactive or milder JIA

Prevalence and severity of oral and TMJ diseases/conditions (periodontal status and dental caries) · Children and adolescents with juvenile idiopathic arthritis (JIA)

Some studies suggested greater JIA disease activity/severity (and certain medications) was associated with worse periodontal and caries outcomes, but small samples meant no solid conclusion could be drawn (ungraded).

1 finding from 1 review